Anaptysbio Share Price (NASDAQ: ANAB)

$20.34

▲

0.21

(1.04%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Anaptysbio Stock chart to analyse performance

Anaptysbio stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$20.03
Today's High:$20.43
$20.34
1.52%
Downside
Day's Volatility :1.96%
Upside
0.44%
52 Weeks Low:$12.21
52 Weeks High:$40.70
$20.34
39.97%
Downside
52 Weeks Volatility :70.0%
Upside
50.02%

Anaptysbio Stock Returns

Period	Anaptysbio Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-7.07%	3.6%	0.0%
6 Months	38.76%	-7.7%	0.0%
1 Year	-43.69%	-12.6%	0.0%
3 Years	-17.95%	10.2%	-4.1%

Anaptysbio Inc Key Stats

Check Anaptysbio key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$20.13
Open	$20.065
Today's High	$20.43
Today's Low	$20.03
Market Capitalization	$570.6M
Today's Volume	$322.6K
52 Week High	$40.7
52 Week Low	$12.21
Revenue TTM	$123.2M
EBITDA	$-85.6M
Earnings Per Share (EPS)	$-4.39
Profit Margin	-107.66%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-343.83%

Stock Returns calculator for Anaptysbio Stock including INR - Dollar returns

The Anaptysbio stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Anaptysbio investment value today

Current value as on today

₹61,659

Returns

₹38,341

(-38.34%)

Returns from Anaptysbio Stock

₹43,625 (-43.63%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Anaptysbio Stock

-36%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Anaptysbio Stock from India on INDmoney has decreased by -36% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Anaptysbio Inc

Name
Holdings %
Name
Holdings %
EcoR1 Capital, LLC
28.17%
First Light Asset Management, LLC
12.65%
Point72 Asset Management, L.P.
8.85%
BlackRock Inc
7.78%
FMR Inc
6.81%
Vanguard Group Inc
5.50%

Analyst Recommendation on Anaptysbio Stock

Rating

Trend

Buy

75%Buy

25%Hold

0%Sell

Based on 16 Wall street analysts offering stock ratings for Anaptysbio(by analysts ranked 0 to 5 stars)

Anaptysbio Share Price Target

What analysts predicted

Upside of 123.7%

Target:

$45.50

Current:

$20.34

Anaptysbio share price target is $45.50, a slight Upside of 123.7% compared to current price of $20.34 as per analysts' prediction.

Anaptysbio Stock Insights

Price Movement
In the last 1 month, ANAB stock has moved down by -17.3%
Decreasing Revenue
Revenue is down for the last 3 quarters, 43.11M → 22.26M (in $), with an average decrease of 27.7% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -39.32M → -38.63M (in $), with an average increase of 1.8% per quarter
ANAB vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 116.6%
ANAB vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.0% return, outperforming this stock by 128.5%
Price to Sales
ForANAB every $1 of sales, investors are willing to pay $4.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Anaptysbio Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$8.0M	↑ 60.0%
Net Income	$-97.3M	↑ 57.87%
Net Profit Margin	-1.2K%	↑ 16.42%

	FY20	Y/Y Change
Revenue	$75.0M	↑ 837.5%
Net Income	$-19.9M	↓ 79.53%
Net Profit Margin	-26.56%	↑ 1190.14%

	FY21	Y/Y Change
Revenue	$63.2M	↓ 15.77%
Net Income	$-57.2M	↑ 187.11%
Net Profit Margin	-90.53%	↓ 63.97%

	FY22	Y/Y Change
Revenue	$10.3M	↓ 83.72%
Net Income	$-128.7M	↑ 125.07%
Net Profit Margin	-1.3K%	↓ 1160.8%

	FY23	Y/Y Change
Revenue	$17.2M	↑ 66.78%
Net Income	$-163.6M	↑ 27.11%
Net Profit Margin	-953.66%	↑ 297.67%

	FY24	Y/Y Change
Revenue	$91.3M	↑ 432.03%
Net Income	$-145.2M	↓ 11.24%
Net Profit Margin	-159.1%	↑ 794.56%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$7.2M	↓ 20.28%
Net Income	$-43.9M	↑ 4.09%
Net Profit Margin	-612.01%	↓ 143.26%

	Q2 FY24	Q/Q Change
Revenue	$11.0M	↑ 52.82%
Net Income	$-46.7M	↑ 6.2%
Net Profit Margin	-425.3%	↑ 186.71%

	Q3 FY24	Q/Q Change
Revenue	$30.0M	↑ 173.6%
Net Income	$-32.9M	↓ 29.59%
Net Profit Margin	-109.44%	↑ 315.86%

	Q4 FY24	Q/Q Change
Revenue	$43.1M	↑ 43.63%
Net Income	$-21.8M	↓ 33.69%
Net Profit Margin	-50.53%	↑ 58.91%

	Q1 FY25	Q/Q Change
Revenue	$27.8M	↓ 35.59%
Net Income	$-39.3M	↑ 80.54%
Net Profit Margin	-141.62%	↓ 91.09%

	Q2 FY25	Q/Q Change
Revenue	$22.3M	↓ 19.83%
Net Income	$-38.6M	↓ 1.78%
Net Profit Margin	-173.52%	↓ 31.9%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-91.3M	↑ 78.41%

	FY20	Y/Y Change
Profit	$-5.0M	↓ 94.5%

	FY21	Y/Y Change
Profit	$-35.3M	↑ 602.91%

	FY22	Y/Y Change
Profit	$8.0M	↓ 122.51%

	FY23	Y/Y Change
Profit	$14.8M	↑ 85.88%

	FY24	Y/Y Change
Profit	$91.3M	↑ 517.55%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$6.6M	↓ 21.75%

	Q2 FY24	Q/Q Change
Profit	$10.4M	↑ 57.83%

	Q3 FY24	Q/Q Change
Profit	$29.4M	↑ 183.55%

	Q4 FY24	Q/Q Change
Profit	$43.1M	↑ 46.54%

	Q1 FY25	Q/Q Change
Profit	$27.8M	↓ 35.59%

	Q2 FY25	Q/Q Change
Profit	$21.7M	↓ 22.0%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-69.5M	↑ 43.32%
Investing Cash Flow	$131.4M	↓ 192.26%
Financing Cash Flow	$-4.5M	↓ 102.01%

	FY20	Y/Y Change
Operating Cash Flow	$-14.2M	↓ 79.64%
Investing Cash Flow	$94.5M	↓ 28.12%
Financing Cash Flow	$-879.0K	↓ 80.44%

	FY21	Y/Y Change
Operating Cash Flow	$-45.9M	↑ 224.36%
Investing Cash Flow	$38.8M	↓ 58.89%
Financing Cash Flow	$252.3M	↓ 28802.84%

	FY22	Y/Y Change
Operating Cash Flow	$-73.6M	↑ 60.26%
Investing Cash Flow	$-394.8M	↓ 1116.72%
Financing Cash Flow	$44.0M	↓ 82.55%

	FY23	Y/Y Change
Operating Cash Flow	$-120.8M	↑ 64.15%
Investing Cash Flow	$144.8M	↓ 136.66%
Financing Cash Flow	$-59.3M	↓ 234.71%

	FY24	Y/Y Change
Operating Cash Flow	$-135.3M	↑ 12.03%
Investing Cash Flow	$95.4M	↓ 34.1%
Financing Cash Flow	$127.1M	↓ 314.27%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-44.2M	↑ 28.66%
Investing Cash Flow	$68.6M	↑ 39.53%
Financing Cash Flow	$-6.7M	↑ 29.73%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-14.4M	↓ 67.46%
Investing Cash Flow	$-2.4M	↓ 103.56%
Financing Cash Flow	$35.0M	↓ 622.19%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-10.1M	↓ 29.84%
Investing Cash Flow	$58.6M	↓ 2500.49%
Financing Cash Flow	$71.2M	↑ 103.81%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-66.7M	↑ 560.77%
Investing Cash Flow	$-29.4M	↓ 150.15%
Financing Cash Flow	$27.6M	↓ 61.3%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-10.7M	↓ 83.95%
Investing Cash Flow	$14.8M	↓ 150.51%
Financing Cash Flow	$-28.6M	↓ 203.71%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-40.2M	↑ 276.11%
Investing Cash Flow	$36.4M	↑ 145.19%
Financing Cash Flow	$-50.5M	↑ 76.63%

Anaptysbio Technicals Summary

Sell

Neutral

Buy

Anaptysbio is currently in a neutral trading position according to technical analysis indicators.

Anaptysbio Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Anaptysbio Inc	-17.72%	38.76%	-43.69%	-17.95%	17.63%
Regeneron Pharmaceuticals, Inc.	3.92%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	2.49%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-15.42%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	11.08%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Anaptysbio Inc	NA	NA	0.0	-4.8	-3.44	-0.14	NA	-1.6
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Anaptysbio Inc	Buy	$570.6M	17.63%	NA	-107.66%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Anaptysbio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Organization	Anaptysbio
Employees	136
CEO	Mr. Daniel R. Faga
Industry	Health Technology

Key Management of Anaptysbio Inc

Name	Title
Mr. Daniel R. Faga	President, CEO & Director
Mr. Dennis M. Mulroy	Chief Financial Officer
Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.	Chief Medical Officer
Mr. Eric J. Loumeau	Chief Legal Officer
Ms. Beth Mueller	Senior Vice President of Human Resources
Dr. Martin Dahl Ph.D.	Senior Vice President of Research
Mr. Benjamin Stone	Chief Business Officer
Mr. Douglas A. Rich M.B.A.	Senior Vice President of CMC
Ms. Monique Da Silva	Senior Vice President of Corporate Affairs
Ms. Priya Raina	Senior Vice President of Clinical Operations

Important FAQs about investing in ANAB Stock from India :

What is Anaptysbio share price today?

Anaptysbio share price today is $20.34 as on August 30, 2025 at 1:29 am IST at the close of the market. Anaptysbio share today touched a day high of $20.43 and a low of $20.03.

What is the 52 week high and 52 week low for Anaptysbio share?

Anaptysbio share touched a 52 week high of $40.70 and a 52 week low of $12.21. Anaptysbio stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $20.34, lower by 50.02% versus the 52 week high.

How to invest in Anaptysbio Stock (ANAB) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Anaptysbio on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Anaptysbio Shares that will get you 0.0737 shares as per Anaptysbio share price of $20.34 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Anaptysbio Stock (ANAB) from India?

Indian investors can start investing in Anaptysbio (ANAB) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Anaptysbio stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Anaptysbio share’s latest price of $20.34 as on August 30, 2025 at 1:29 am IST, you will get 0.4916 shares of Anaptysbio. Learn more about fractional shares .

What are the returns that Anaptysbio has given to Indian investors in the last 5 years?

Anaptysbio stock has given 17.63% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?